Spotlight On... Transdermal iron patch maker raises $11M in Series B round featuring Chinese investors; FDA clarifies fecal transplant regs; Top execs discuss drug delivery at round table; and more

Fe3 Medical raised $11M in a Series B round as it seeks funding to achieve FDA and CE mark approval of its transdermal iron patch to treat iron-deficiency anemia. Participants in the round were InCube Ventures, HG Capital, Chinese VC firm PingAn Ventures and strategic Chinese investor Jianmin Pharmaceuticals. "Fe3 was created to address a clear, unmet clinical need as nearly half of the patients suffering from iron-deficiency anemia cannot tolerate oral iron," said Mir Imran, chairman and CEO of InCube Labs. "Our therapy is a compelling alternative to millions of patients, giving them the iron they need without the undesirable side effects of oral iron." More from FierceMedicalDevices

> The FDA said it will opt to not regulate administration of fecal transplantation to treat C. difficile infection not responding to standard therapies. More

Pharm Exec recently ran Q&As with four execs, focused on, you guess it, drug delivery. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.